## One–year all–cause mortality and other clinical outcomes in patients with obesity and CRC (comparison between matched semaglutide vs other anti–obesity medication cohorts)

| Outcomes | Semaglutide (n = 557) | Other anti–obesity medications (n = 557) | | HR (95% CI) |
|---|---|---|---|---|
| All–cause mortality | <10 (<1.8%) | 35 (6.3%) | | 0.19 (0.08–0.43) |
| Hospitalization | 127 (22.8%) | 228 (40.9%) | | 0.46 (0.37–0.57) |
| ED visits | 164 (29.4%) | 192 (34.5%) | | 0.75 (0.61–0.93) |
| ICU admission | 19 (3.4%) | 39 (7.0%) | | 0.45 (0.26–0.79) |
| **Control Outcomes** | | | | |
| Overall medical encounters | 555 (99.6%) | 551 (98.9%) | | 1.07 (0.95–1.20) |
| Outpatient medical encounters | 529 (95.0%) | 518 (93.0%) | | 1.08 (0.96–1.22) |



Hazard Ratio (HR)

0.10  0.20  0.40  0.70  2.0 3.00 5.00 8.00